10-Q: Prothena Reports Q2 Loss, Halts Birtamimab, Cuts Workforce

Prothena Corporation plc reported a significant net loss in Q2 2025, driven by the discontinuation of its birtamimab program and a substantial workforce reduction, while advancing its key neuroscience pipeline.

Summary

• Prothena reported a net loss of $186.0 million for the six months ended June 30, 2025, a significant increase from a net loss of $5.4 million for the same period in 2024.
• Total revenue decreased by 95% to $7.2 million for the six months ended June 30, 2025, compared to $132.1 million in the prior year, primarily due to lower collaboration revenue.
• Research and development (R&D) expenses decreased by 25% to $91.3 million for the six months ended June 30, 2025, from $121.6 million in the prior year, mainly due to lower clinical trial and manufacturing expenses for PRX012.
• The company incurred $32.6 million in restructuring costs for the three and six months ended June 30, 2025, following the discontinuation of birtamimab development and an approximate 63% workforce reduction.
• Cash and cash equivalents stood at $371.4 million as of June 30, 2025, down from $471.4 million at December 31, 2024, with net cash used in operating activities increasing to $99.7 million from $57.1 million in the prior year period.
• Roche will advance prasinezumab into Phase 3 development for early-stage Parkinson's disease, citing positive trends from the Phase 2b PADOVA study and long-term follow-up data.
• BMS initiated a Phase 2 clinical trial for BMS-986446 in Q1 2024 and a Phase 1 clinical trial for subcutaneous BMS-986446 in Q2 2025.
• PRX012 and PRX123, wholly-owned Alzheimer's programs, received FDA Fast Track designation, with initial Phase 1 data for PRX012 expected in August 2025.
• The company entered into a global license agreement with BMS for PRX019 in May 2024, receiving an $80.0 million option exercise fee and eligible for up to $617.5 million in additional milestones.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the significant financial losses, sharp revenue decline, discontinuation of a late-stage program (birtamimab), and a substantial workforce reduction. While there are positive updates on other pipeline assets advancing, the immediate financial impact and the failure of a key program overshadow these developments, indicating a challenging period for the company.

Positives

• Roche is advancing prasinezumab into Phase 3 development for early-stage Parkinson's disease, indicating continued confidence in the program's potential.
• Phase 2b PADOVA study for prasinezumab showed potential clinical effect on motor progression and provided the first biomarker evidence of impacting underlying disease biology.
• BMS-986446, an anti-tau antibody for Alzheimer's, is progressing with a Phase 2 clinical trial initiated in Q1 2024 and a Phase 1 subcutaneous trial in Q2 2025, demonstrating robust CSF exposure in earlier Phase 1.
• PRX012, an Alzheimer's antibody, received FDA Fast Track designation and Phase 1 data supports single-injection once-monthly subcutaneous treatment and dose escalation.
• PRX123, a dual A-tau vaccine for Alzheimer's, received FDA Fast Track designation and IND clearance, showing promising preclinical data.
• The global license agreement for PRX019 with BMS generated an $80.0 million option exercise fee and offers potential for up to $617.5 million in future development, regulatory, and sales milestones.
• The company has earned $100 million to date from the Novo Nordisk agreement for coramitug and is eligible for up to $1.13 billion in additional development and sales milestones.

Negatives

• The company reported a substantial net loss of $186.0 million for the six months ended June 30, 2025, significantly higher than the $5.4 million loss in the prior year period.
• Total revenue plummeted by 95% to $7.2 million for the six months ended June 30, 2025, compared to $132.1 million in the same period last year.
• The discontinuation of birtamimab development, a late-stage program, due to failure in Phase 3 AFFIRM-AL clinical trial, represents a significant setback.
• An approximate 63% reduction in workforce was implemented in June 2025, indicating a major corporate restructuring and impact on employees.
• Restructuring costs of $32.6 million were incurred, primarily for employee termination benefits and contract termination costs related to birtamimab.
• Cash and cash equivalents decreased to $371.4 million from $471.4 million, and net cash used in operating activities increased to $99.7 million, indicating a higher cash burn rate.
• A full valuation allowance of $44.9 million was recorded against federal deferred tax assets, reflecting management's belief that it is not more likely than not that the company will realize the benefits of these assets.

Risks

• The company anticipates incurring losses for the foreseeable future and may never sustain profitability.
• Additional capital will be required to fund operations, and if unavailable, the company may be unable to successfully develop and commercialize drug candidates.
• Success is largely dependent on research and development programs, which are in various stages and may not successfully lead to regulatory approval or commercialization.
• Collaborations with Roche, BMS, and Novo Nordisk may not realize anticipated benefits, including milestone payments.
• Clinical trials of drug candidates may be prolonged, delayed, suspended, or terminated, leading to additional costs and delayed revenue.
• Even if approved, drug candidates may not achieve broad market acceptance, limiting potential revenues.
• Inability to adequately protect or enforce intellectual property relating to drug candidates could harm commercialization efforts.
• Future success depends on the ability to retain key personnel and attract, retain, and motivate qualified personnel.
• The company may be adversely affected by business disruptions beyond its control, including public health crises, geopolitical turmoil, and natural disasters.
• Breaches or similar disruptions of information technology systems or data could occur, impacting operations and data security.
• Changes in and failures to comply with U.S. and foreign privacy and data protection laws, regulations, and standards may adversely affect business.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The FDA or other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• Drug candidates are subject to ongoing regulatory requirements and continued review, with potential sanctions for non-compliance.
• Identification of side effects during development or post-market could lead to additional clinical trials, labeling changes, or product withdrawal.
• The company deals with hazardous materials and must comply with environmental laws, which can be expensive and restrict business.
• The markets for drug candidates are subject to intense competition, potentially rendering products noncompetitive or obsolete.
• Drug candidates intended as biologic products may face biosimilar competition sooner than anticipated.
• The company may be unable to maintain the benefits associated with Orphan Drug Designation, including market exclusivity.
• Fast Track designation may not lead to faster development or regulatory review and does not assure marketing licensure.
• The company is subject to healthcare and other laws and regulations, including anti-bribery, anti-kickback, fraud and abuse, false claims, and physician payment transparency laws, which could lead to sanctions.
• A successful product liability or clinical trial claim could result in substantial uninsured or excess liabilities.
• Reliance on third parties to conduct clinical trials and manufacture supplies poses risks of unsatisfactory performance or supply interruptions.
• The company may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• Changes in U.S. patent law could diminish the value of patents, impairing the ability to protect products.
• The lives of patents may not be sufficient to effectively protect products and business.
• Litigation regarding patents, patent applications, and other proprietary rights may be expensive and time-consuming.
• Inadequate protection of trademarks and trade names could hinder name recognition and adversely affect business.
• Inability to adequately prevent disclosure or misappropriation of trade secrets and other proprietary information could erode competitive position.
• The market price of ordinary shares may fluctuate widely due to various factors.
• Percentage ownership in Prothena may be diluted in the future due to equity issuances.
• Inability to maintain effective internal controls could adversely affect business.
• Being treated as a passive foreign investment company (PFIC) for U.S. federal income tax purposes could result in adverse consequences for U.S. holders.
• Inability to successfully maintain tax rates could adversely affect business and financial condition.
• Irish law differs from U.S. law, potentially affording less protection to shareholders and affecting takeover proposals.
• Irish law requires shareholders to renew Board authority to issue shares and opt out of pre-emption rights every five years, impacting capital raising ability.
• Transfers of ordinary shares may be subject to Irish stamp duty.
• The company does not anticipate paying cash dividends, requiring shareholders to rely on share appreciation for return.
• Dividends paid by the company may be subject to Irish dividend withholding tax.
• Ordinary shares received by gift or inheritance could be subject to Irish capital acquisitions tax.

Future Outlook

The company expects to report initial data from its Phase 1 clinical trials for PRX012 in August 2025. It plans to advance PRX012 and PRX123 programs through non-dilutive and capital efficient structures. Management believes existing cash and cash equivalents are sufficient for at least the next twelve months but anticipates requiring substantial additional capital beyond that period to fund operations, including research, development, and eventual commercialization of drug candidates. Future capital needs are expected to be financed through payments from existing collaborations (Roche, BMS, Novo Nordisk) and, if necessary, through public or private equity or debt financings.

Management Comments

• "Based on our current business plans, we believe that our existing cash and cash equivalents at June 30, 2025 are sufficient to meet our obligations for at least the next twelve months."
• "To operate beyond such period, or if we elect to increase our spending on research and development programs significantly above current long-term plans or enter into potential licenses and/or other acquisitions of complementary technologies, products or companies, we may need additional capital."
• "Additionally, in order to develop and obtain regulatory approval for our potential products we will need to raise substantial additional capital."
• "We expect to continue to finance future capital needs that exceed our existing cash and cash equivalents from payments pursuant to our agreements with Roche, BMS, and Novo Nordisk, and, to the extent necessary, other collaborative agreements with corporate partners, or other arrangements, and through proceeds from public or private equity or debt financings, and loans including pursuant to the Amended Distribution Agreement."
• "We cannot assume that such additional financings will be available on acceptable terms, if at all, and such financings may only be available on terms dilutive to its shareholders."
• "Assuming no significant change in our business, we expect the full year 2025 net cash used in operating and investing activities to be approximately $170 million to $178 million."

Industry Context

The biotechnology industry, particularly in neurodegenerative diseases, is characterized by high risk, long development timelines, and significant capital requirements. Prothena's focus on Alzheimer's and Parkinson's diseases addresses areas with immense unmet medical needs and large patient populations. The advancement of prasinezumab to Phase 3 by Roche is a notable step in the competitive Parkinson's disease landscape, where disease-modifying therapies are highly sought after. Similarly, the continued development of anti-amyloid beta (PRX012) and anti-tau (BMS-986446, PRX123) therapies for Alzheimer's disease aligns with major industry efforts to tackle these complex conditions, following recent regulatory approvals for amyloid-targeting drugs. The discontinuation of birtamimab highlights the inherent high failure rate in late-stage drug development, a common challenge across the biopharmaceutical sector.

Comparison to Industry Standards

• The advancement of prasinezumab into Phase 3 development for early-stage Parkinson's disease by Roche positions it as a leading anti-alpha-synuclein antibody, a novel approach compared to existing symptomatic treatments for Parkinson's disease.
• The positive trends observed in the Phase 2b PADOVA study for prasinezumab, including potential clinical effect on motor progression and biomarker evidence, suggest a differentiated profile in a field where many prior alpha-synuclein targeting therapies have faced challenges.
• The robust exposure of BMS-986446 in cerebrospinal fluid (CSF) (day 29 CSF:Plasma ratio=0.2%) in Phase 1 is a positive indicator for central nervous system (CNS) target engagement, which is crucial for Alzheimer's therapies and compares favorably to some other CNS-penetrating antibodies.
• PRX012's preclinical demonstration of approximately 10-fold greater affinity/avidity for fibrillar Aβ than aducanumab and neutralization of soluble, toxic Aβ species suggests a potentially improved profile compared to existing or late-stage amyloid-beta targeting antibodies like Biogen/Eisai's Aduhelm (aducanumab) and Leqembi (lecanemab), aiming for similar or improved efficacy with subcutaneous dosing.
• The dual Aβ-tau targeting approach of PRX123 is a differentiated strategy in the Alzheimer's vaccine space, as most current therapies or vaccines target only one of these pathological features, potentially offering a broader therapeutic benefit if successful.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Significant net loss and revenue decline, coupled with potential future dilution from capital raises, could negatively impact share price and investment value. The discontinuation of birtamimab and workforce reduction are major negative events. However, the advancement of other pipeline assets offers long-term potential.
• **Employees**: An approximate 63% workforce reduction will result in job losses and impact morale for remaining employees. This is a severe negative impact.
• **Customers/Patients**: Discontinuation of birtamimab means a potential treatment for AL amyloidosis will not be available. However, continued progress in other programs (Parkinson's, Alzheimer's) offers future therapeutic options for patients in those disease areas.
• **Suppliers/Contractors**: Contract termination costs related to birtamimab manufacturing will impact certain third-party manufacturers. Ongoing collaborations will continue to provide business for other suppliers.
• **Creditors**: Increased accumulated deficit and cash burn could raise concerns, but management believes current cash is sufficient for 12 months, and potential future capital raises are planned.

Next Steps

• Report initial data from Phase 1 clinical trials for PRX012 in August 2025.
• Advance PRX012 and PRX123 programs through non-dilutive and capital efficient structures.
• Continue to finance future capital needs through existing collaborations and potentially new equity or debt financings.
• Roche to continue Phase 3 development for prasinezumab.
• BMS to continue Phase 1 and Phase 2 clinical trials for BMS-986446.
• Continue Phase 1 first-in-human clinical trial for PRX019.

Key Dates

Recommendation

While the company reported a substantial net loss, a sharp decline in revenue, and incurred significant restructuring costs due to the discontinuation of its birtamimab program and a major workforce reduction, these actions represent a necessary strategic pivot to conserve capital. The remaining pipeline, particularly prasinezumab advancing to Phase 3 with Roche and the wholly-owned Alzheimer's programs (PRX012, PRX123) with Fast Track designations, still holds significant long-term value in large, underserved markets. The company also has substantial potential milestone payments from existing collaborations. Given the severe short-term financial headwinds but the continued progression of high-potential assets and a clear strategy to manage liquidity, a 'hold' recommendation is appropriate for investors willing to tolerate near-term volatility for potential long-term upside, rather than a 'sell' which would imply a complete loss of confidence in the pipeline.

Keywords

Biotechnology, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, ATTR amyloidosis, Drug development, Clinical trials, Monoclonal antibody, PRX012, PRX019, PRX123, Prasinezumab, BMS-986446, Protein dysregulation, SEC filing, 10-Q